Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairmentChen‐Hua Liu, Jia‐Horng Kao, Cheng‐Yuan Peng et al.|Gut|2021Cited by 39
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosisChen‐Hua Liu, Jia‐Horng Kao, Chi-Yi Chen et al.|Clinical and Molecular Hepatology|2021Cited by 22
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in TaiwanChen‐Hua Liu, Jia‐Horng Kao, Cheng‐Yuan Peng et al.|Hepatology International|2023Cited by 21
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus InfectionYu‐Ping Chang, Ji‐Yuh Lee, Chi‐Yi Chen et al.|Alimentary Pharmacology & Therapeutics|2025Cited by 12